Hundreds of consumers are suing manufacturers of GLP-1 weight-loss drugs, claiming they cause NAION, a rare eye condition leading to sudden vision loss. Research shows mixed results with some studies finding increased NAION risk in semaglutide users, though observational evidence cannot prove causation, and regulatory agencies remain under investigation without issuing formal warnings.